¼¿ï¼º¸ðº´¿ø ´Ù¹ß°ñ¼öÁ¾¿¬±¸È¸ Update on MM 2020 (ASH review) : 2020-02-08±³À°ÀÏÀÚ : 2020-02-08
±³À°Àå¼Ò : °¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø ÁöÇÏ 1Ãþ ´ë°´ç
±³À°ÁÖÁ¦ :
Update on MM 2020 (ASH review)ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´Ù¹ß°ñ¼öÁ¾¿¬±¸È¸
´ã´çÀÚ : ¼È¿Áø
¿¬¶ôó : 02-516-6581
À̸ÞÀÏ :
kmmwp_office@naver.com ±³À°Á¾·ù : ³»°ú, Áø´Ü°Ë»çÀÇÇаú
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 5 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02-08 ¼¿ï¼º¸ðº´¿ø ÁöÇÏ 1Ãþ ´ë°´ç 10:30~11:00 Genomics and epigenomics of MM °í¿µÀÏ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 02-08 ¼¿ï¼º¸ðº´¿ø ÁöÇÏ 1Ãþ ´ë°´ç 11:00~11:30 Rare diseases including Amyloidosis, POEMS and WM Á¶Àçö(¿ï»êÀÇ´ë)
±³À°½Ã°£ 02-08 ¼¿ï¼º¸ðº´¿ø ÁöÇÏ 1Ãþ ´ë°´ç 11:30~12:00 MGUS and smoldering MM °°¡¿ø(°í·ÁÀÇ´ë)
±³À°½Ã°£ 02-08 ¼¿ï¼º¸ðº´¿ø ÁöÇÏ 1Ãþ ´ë°´ç 12:00~12:30 Imaging approaches for MM ¹®ÁØÈ£(°æºÏÀÇ´ë)
±³À°½Ã°£ 02-08 ¼¿ï¼º¸ðº´¿ø ÁöÇÏ 1Ãþ ´ë°´ç 13:30~14:00 Treatment of Newly Diagnosed Myeloma Transplant Eligible: induction and transplantation ÀÌÁöÇö(µ¿¾ÆÀÇ´ë)
±³À°½Ã°£ 02-08 ¼¿ï¼º¸ðº´¿ø ÁöÇÏ 1Ãþ ´ë°´ç 14:00~14:30 Treatment of Newly Diagnosed Myeloma Non-Transplant ±èÀ¯¸®(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 02-08 ¼¿ï¼º¸ðº´¿ø ÁöÇÏ 1Ãþ ´ë°´ç 14:30~15:00 Consolidation and Maintenance Strategies for MM ÀÌÀ¯Áø(¿ï»êÀÇ´ë)
±³À°½Ã°£ 02-08 ¼¿ï¼º¸ðº´¿ø ÁöÇÏ 1Ãþ ´ë°´ç 15:15~15:45 Treatment Options for Relapsed/Refractory patients other than immunotherapeutics º¯ÀÚ¹Î(¼¿ïÀÇ´ë)
±³À°½Ã°£ 02-08 ¼¿ï¼º¸ðº´¿ø ÁöÇÏ 1Ãþ ´ë°´ç 15:45~16:15 Immunologic treatment options for RRMM other than cellular therapy ÃÖÀ±¼®(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 02-08 ¼¿ï¼º¸ðº´¿ø ÁöÇÏ 1Ãþ ´ë°´ç 16:15~16:45 Cellular Immunotherapies for MM À±»óÀº(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 02-08 ¼¿ï¼º¸ðº´¿ø ÁöÇÏ 1Ãþ ´ë°´ç 16:45~17:15 MRD assessment ÀÓÁöÇâ(°¡Å縯ÀÇ´ë)